Hello and welcome back to a spooky Halloween edition of Endpoints Weekly! Sorry to all the candy corn lovers out there, but ...
Aspen Neuroscience raises ~$141M and Bambusa ~$169M in Nasdaq IPOs, pushing 2026 biotech IPO haul to ~$8B across 29 deals.
Sanofi will keep launching new medicines across Europe under Trump’s MFN policy, possibly at higher prices, its CFO says.
Gilead pauses KITE-753 trials over ICANS; Agios' mitapivat PDUFA delayed; Acumen scraps sabirnetug; BMS drops BMS-986495; ...
AstraZeneca's CEO Pascal Soriot & CFO Aradhana Sarin outline restructuring: cuts near Farxiga/Brilinta, reinvesting $1.5B in ...
AstraZeneca launches a restructuring to save $1.5B a year for R&D, beats Q3 sales forecasts and cuts several trials, ...
Bristol Myers touts 7% Q3 revenue growth and admilparant progress as it faces 2028 patent cliffs for Eliquis and Opdivo.
Merck’s head of R&D Dean Li believes he’s outfoxed his competition for the next generation of oncology drugs, ...
Vertex, Kindeva and Convatec pledge £1B+ for UK sites in Healey’s first Budget; Teva closes NJ plant; Regeneron extends ...
AI agents are booking medical appointments & fighting insurance denials. Zocdoc welcomes agents; General Medicine designs ...
Dren Bio raises $350M to advance blood cancer drug dibotatug toward 2027 market launch, backed by Juvia Group and Lightspeed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results